Context Therapeutics (CNTX) Earnings Date, Estimates & Call Transcripts $0.83 -0.01 (-1.76%) Closing price 04:00 PM EasternExtended Trading$0.82 0.00 (-0.50%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Context Therapeutics Earnings Summary Context Therapeutics announced Q2 2025 earnings on August 6, 2025, reporting an EPS of -$0.09, which missed analysts' consensus estimates of -$0.06 by $0.03. With a trailing EPS of -$0.36, Context Therapeutics' earnings are expected to grow next year, from ($0.51) to ($0.31) per share. Upcoming Q3 Earnings DateNov. 5Before Market OpensEstimatedConsensus EPS (Aug. 6) -$0.06 Actual EPS (Aug. 6) -$0.09 Missed By -$0.03 Q2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)CNTX Upcoming EarningsContext Therapeutics' next earnings date is estimated for Wednesday, November 5, 2025, based on past reporting schedules. Powered by Get Context Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataCNTX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Context Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.05-$0.05-$0.05Q2 20252-$0.06-$0.05-$0.06Q3 20252-$0.09-$0.06-$0.08Q4 20252-$0.09-$0.06-$0.08 FY 2025 7 -$0.29 -$0.22 -$0.26 Q1 20261-$0.09-$0.09-$0.09Q2 20261-$0.09-$0.09-$0.09Q3 20261-$0.08-$0.08-$0.08Q4 20261-$0.07-$0.07-$0.07 Context Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/5/2025(Estimated)--------8/6/2025Q2 2025-$0.06-$0.09 -$0.03-$0.09--5/14/2025Q1 2025-$0.05-$0.05--$0.05--3/20/2025Q4 2024-$0.05-$0.04+$0.01---11/6/2024--$0.11-$0.22 -$0.11-$0.22--8/7/2024--$0.08-$0.04+$0.04-$0.04--5/8/2024Q1 2024-$0.38-$0.23+$0.15-$0.23--3/21/2024Q4 2023-$0.35-$0.42 -$0.07-$0.42--11/9/2023Q3 2023-$0.30-$0.37 -$0.07-$0.37-- Context Therapeutics Earnings - Frequently Asked Questions When is Context Therapeutics' earnings date? Context Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 5th, 2025 based off last year's report dates. Learn more on CNTX's earnings history. Did Context Therapeutics beat their earnings estimates last quarter? In the previous quarter, Context Therapeutics (NASDAQ:CNTX) missed the analysts' consensus estimate of ($0.06) by $0.03 with a reported earnings per share (EPS) of ($0.09). Learn more on analysts' earnings estimate vs. CNTX's actual earnings. How much profit does Context Therapeutics generate each year? Context Therapeutics (NASDAQ:CNTX) has a recorded net income of -$26.73 million. CNTX has generated -$0.36 earnings per share over the last four quarters. What is Context Therapeutics' EPS forecast for next year? Context Therapeutics' earnings are expected to grow from ($0.51) per share to ($0.31) per share in the next year. More Earnings Resources from MarketBeat Related Companies DMAC Earnings Results FHTX Earnings Results ALT Earnings Results DRUG Earnings Results CGC Earnings Results DSGN Earnings Results GLUE Earnings Results OCGN Earnings Results RNAC Earnings Results AVIR Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Affirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 Outlook This page (NASDAQ:CNTX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
